New Low-Dose treatment shows promise for blood disorder
NCT ID NCT01719692
Summary
This study tested two different low-dose treatment schedules of the drug rituximab for adults with immune thrombocytopenia (ITP), a condition where the immune system attacks blood platelets. Researchers compared giving 100 mg weekly for four weeks versus a single larger dose to see which worked better and was better tolerated. The trial involved 100 Chinese adult patients whose ITP didn't respond well to or came back after steroid treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIC PURPURA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital of Blood disease
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.